Lidocaine Infusion On Hysteroscopic Media Versus Oral Diclofinac For Pain Relief During Outpatient Hysteroscopy
NCT ID: NCT03298646
Last Updated: 2017-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
44 participants
INTERVENTIONAL
2017-10-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lidacaine hydrochloride
Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.
22 women.
Lidocaine Hydrochloride
10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
Diclofenac
100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.
22 women.
Diclofenac
100 mg Diclofenac oral tablet one hour before the procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine Hydrochloride
10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
Diclofenac
100 mg Diclofenac oral tablet one hour before the procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 18.5-30 Kg.
* Nulliparous women assigned for diagnostic hysteroscopy.
* Informed written consent.
Exclusion Criteria
* Cervical stenosis.
* Known gastritis.
* Recent or active PID.
* Cardiac patients.
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Elsayed Hassan Elbohoty
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams maternity hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
ahmed elbohoty
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hysteroscopy
Identifier Type: -
Identifier Source: org_study_id